Nevro Spinal Cord Stimulator Lawsuit
Updated November 2, 2026. Nevro is unusual: it has zero FDA-classified recalls on record, yet the MAUDE database logged 2,478 adverse-event reports for its devices between January 2024 and July 2026. Nevro cases now have their own MDL: on October 2, 2026, after its September 24 hearing session, the JPML centralized them as MDL-3195 in the Northern District of California before Judge Haywood S. Gilliam, Jr. Globus Medical, which acquired Nevro, is a co-defendant. There is no verdict and no settlement.
Key Takeaways
- Nevro has zero FDA-classified recalls on record, the only major SCS manufacturer with none, a verified finding
- Yet the FDA MAUDE database logged 2,478 adverse-event reports for Nevro devices from January 2024 to July 2026
- Nevro cases are now centralized as MDL-3195 in the Northern District of California before Judge Haywood S. Gilliam, Jr. by a JPML order of October 2, 2026, and Globus Medical is a co-defendant. Initial status conference: December 18, 2026
- DiToto v. Nevro (May 2026) is the most plaintiff-favorable SCS ruling found; Yusnukis and Greene were dismissed, though Yusnukis remains open on a request to amend. Courts are split
- The one-year filing deadline risk from the Schiltz order may apply; there is no verdict or settlement
Zero recalls, thousands of reports
The most distinctive fact about Nevro is one that cuts both ways. Nevro has no FDA-classified recall on record for its spinal cord stimulator devices, a finding we verified through several independent checks and one that sets it apart from Abbott, Boston Scientific, and Medtronic. At the same time, the FDA MAUDE adverse-event database recorded 2,478 reports for Nevro devices between January 2024 and July 2026. The absence of a recall is not the same as an absence of reported problems, and MAUDE reports are unverified complaints rather than proven defects, so both facts belong on the page.
A new MDL, and Globus is in the case
A centralization petition against Nevro was filed on June 26, 2026, asking for the Central District of California or, as an alternative, the Northern District of California. A JPML Hearing Session Order filed August 14, 2026 set it for the Panel's September 24, 2026 hearing session in Chicago, and on October 2, 2026 the Panel granted it, creating MDL-3195 in the Northern District of California, where Nevro is headquartered, before Judge Haywood S. Gilliam, Jr., who already presided over all twelve of the district's actions on the motion. Nevro opposed centralization. The Panel found the cases share questions about Nevro's use of the PMA-supplement process, its warnings, and its sales representatives' training and conduct, and that centralization will streamline briefing on Nevro's preemption defenses. It counted 23 actions in ten districts and noted that movants' counsel says it represents 300 potential plaintiffs. Several plaintiffs also bring claims against the FDA, including DiToto. Globus Medical, which acquired Nevro, is named as a co-defendant in many of the cases. The cases transferred into the MDL include DiToto and Yusnukis.
The MDL is at its first organizational stage. In Pretrial Order No. 1, issued October 14, 2026 and amended October 30, Judge Gilliam required applications for plaintiffs' lead counsel and steering committee positions by November 30, 2026, stayed all discovery and briefing on pending motions, and set an initial in-person status conference for December 18, 2026 in Oakland. On October 14 the JPML also conditionally transferred two more Nevro cases from Missouri and Oklahoma. The November 2026 JPML report lists 24 pending actions in MDL-3195; see the MDL-3195 page for its JPML statistics.
The rulings cut both ways
Nevro has produced the sharpest split of authority in the tort. In DiToto v. Nevro, a Maryland federal judge in May 2026 allowed eight counts to proceed and held that failure-to-report claims are not preempted. That is the most plaintiff-favorable spinal cord stimulator decision found to date, and it also allowed a failure-to-train theory to proceed as ordinary negligence. On the other side, the Yusnukis and Greene cases were dismissed on preemption grounds, although the JPML noted in October 2026 that the Yusnukis plaintiff has moved for leave to amend and the action remains open. Both outcomes are on Nevro devices, which is why the first preemption ruling from an MDL judge is expected to be so influential. For Nevro cases, that judge is now Judge Gilliam in MDL-3195, where the Panel expects centralization to streamline briefing on Nevro's preemption defenses.
Devices, deadline, and status
Nevro spinal cord stimulator devices reported in the litigation include the Senza, Senza II, Senza Omnia, and HFX iQ systems. On timing, the July 14, 2026 Schiltz order applied one-year state limitations periods and started the clock when a patient was advised to turn the device off or developed dramatic new symptoms, not at explant. That analysis will not apply in every state, but it makes the filing timeline more urgent than commonly advertised. There is no verdict and no settlement in spinal cord stimulator litigation against Nevro or any other manufacturer, and we do not publish projected per-case figures.
Frequently Asked Questions
Is there a Nevro spinal cord stimulator MDL?
Has Nevro had any FDA recalls?
What have courts said in Nevro cases?
Have there been any Nevro spinal cord stimulator settlements or verdicts?
Sources & References
6 sources cited• FDA Medical Device Recall Database: no classified Nevro SCS recall on record
• FDA MAUDE Database: 2,478 Nevro adverse-event reports (January 2024 to July 2026)
• DiToto v. Nevro, U.S. District Court, District of Maryland (May 2026); Yusnukis and Greene dismissals
• JPML: Nevro centralization petition (filed June 26, 2026) and Hearing Session Order (filed August 14, 2026) setting it for the September 24, 2026 hearing session; Globus Medical as co-defendant
• JPML Transfer Order, MDL No. 3195, In re: Nevro Corporation Spinal Cord Stimulator Products Liability Litigation (October 2, 2026; September 2026 hearing session), and Conditional Transfer Order CTO-1 (October 14, 2026)
• U.S. District Court, Northern District of California: MDL No. 3195, Pretrial Order No. 1 (October 14, 2026; amended October 30, 2026)
• Schiltz order, District of Minnesota (July 14, 2026)
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.